Sign inJoin waitlistJoin the waitlist

Andras Heczey

Director, Liver Tumor Program · Baylor College of Medicine

Credentials: · ·

History

Baylor College of Medicine
Present

Pediatric Hematology/Oncology
Baylor College of Medicine
2012–2015
Baylor College of Medicine - Texas Children's Hospital
2009–2012
Doctor of Medicine
2005–2009

Research

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma
Molecular Therapy · 2017 · First of 18 authors · Corresponding · 451 citations
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy
Blood · 2014 · First of 13 authors · 272 citations
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
Nature Medicine · 2020 · First of 17 authors · Corresponding · 242 citations

Dolores Lopez-Terrada
15 papers
Sanjeev Vasudevan
15 papers
Kalyani Patel
12 papers · 9 as a resident
John Goss
11 papers
Prakash Masand
10 papers
Helen Heslop
8 papers
David Steffin
7 papers · 1 as a fellow
Jennifer Foster
7 papers
Malcolm Brenner
7 papers
Milton Finegold
7 papers
AE
Andres Espinoza
5 papers · 2 as a resident
Angshumoy Roy
5 papers

Grants

pA-Regulator Controlled, JMJD6 Reprogrammed GPC3-CAR T Cells for Patients with Hepatocellular Carcinoma
National Cancer Institute · R21
Contact PI · $470.8K · Seattle Children's Hospital
2025–2027
IL-15 and -21 Armored GPC3-Specific CAR T Cells for Children with Solid Tumors
National Cancer Institute · R01
Contact PI · $3.1M · Seattle Children's Hospital
2022–2026

Clinical trials

T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)
Principal investigator · Withdrawn · Phase 1
Baylor College of Medicine
2020–2038
3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA
Principal investigator · Withdrawn · Phase 1
Baylor College of Medicine
2017–2030
A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells
Principal investigator · Completed · Phase 1, Phase 2
Baylor College of Medicine
2008–2025